Autoimmune hepatitis treatment in the elderly: A systematic review

Table 3 Treatment regimens

Author (year)	Treatments
Schramm et al[6], 2001	P 1 mg/kg/die
	P 1 mg/kg/die + AZA 1-1.5 mg/kg/die
	No treatment
Granito et al[21], 2005	M 1 mg/kg/die
	M 30 mg/die + AZA 50 mg/die
	No treatment
Al-Chalabi et al[23], 2006	P 20-40 mg/die
	P 20-40 mg/die + AZA (1 mg/kg/die)
	P 20-40 mg/die + Cyclo (only in the younger group)
	P 20-40 mg/die + D-P (only in the younger group)
Czaja et al[9], 2006	Pp (doses not specified)
	Pp + AZA (doses not specified)
	Investigational therapies (drugs not specified)
	No Treatment
Zhang et al[22], 2012	P (doses not specified)
	P + AZA (doses not specified)
	No treatment
Zachou et al[20], 2016	P 0,5-1 mg/kg/die + MMF 1.5-2g/die
	P 0,5-1 mg/kg/die
	P 0.5-1 mg/kg/die + AZA 1.5-2 mg/kg/die
Morii et al[24], 2017	Pp 30-40 mg/die
	UDCA (dose not specified)

P: Prednisolone; Pp: Prednisone; AZA: Azathioprine; M: Methylprednisolone; Cyclo: Cyclophosphamide; D-P: D-Penicillamine; MMF: Mycophenolate Mofetil; UDCA: Ursodeoxycholic acid.